Persistent Bacterial Infections, Antibiotic Treatment Failure, and Microbial Adaptive Evolution
- PMID: 35326882
- PMCID: PMC8944626
- DOI: 10.3390/antibiotics11030419
Persistent Bacterial Infections, Antibiotic Treatment Failure, and Microbial Adaptive Evolution
Abstract
Antibiotic resistance is expected by the WHO to be the biggest threat to human health before 2050. In this overview, we argue that this prediction may in fact be too optimistic because it is often overlooked that many bacterial infections frequently 'go under the radar' because they are difficult to diagnose and characterize. Due to our lifestyle, persistent infections caused by opportunistic bacteria-well-known or emerging-show increasing success of infecting patients with reduced defense capacity, and often antibiotics fail to be sufficiently effective, even if the bacteria are susceptible, leaving small bacterial populations unaffected by treatment in the patient. The mechanisms behind infection persistence are multiple, and therefore very difficult to diagnose in the laboratory and to treat. In contrast to antibiotic resistance associated with acute infections caused by traditional bacterial pathogens, genetic markers associated with many persistent infections are imprecise and mostly without diagnostic value. In the absence of effective eradication strategies, there is a significant risk that persistent infections may eventually become highly resistant to antibiotic treatment due to the accumulation of genomic mutations, which will transform colonization into persistence.
Keywords: adaptative evolution; antibiotic resilience; infection persistence.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures

Similar articles
-
An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen.Elife. 2020 Dec 1;9:e58147. doi: 10.7554/eLife.58147. Elife. 2020. PMID: 33258450 Free PMC article.
-
Antibiotic resistance and persistence-Implications for human health and treatment perspectives.EMBO Rep. 2020 Dec 3;21(12):e51034. doi: 10.15252/embr.202051034. Epub 2020 Dec 8. EMBO Rep. 2020. PMID: 33400359 Free PMC article. Review.
-
Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.Elife. 2021 May 18;10:e64116. doi: 10.7554/eLife.64116. Elife. 2021. PMID: 34001313 Free PMC article.
-
Directed evolution of the rRNA methylating enzyme Cfr reveals molecular basis of antibiotic resistance.Elife. 2022 Jan 11;11:e70017. doi: 10.7554/eLife.70017. Elife. 2022. PMID: 35015630 Free PMC article.
-
Pseudomonas aeruginosa: persistence beyond antibiotic resistance.Trends Microbiol. 2025 May 28:S0966-842X(25)00151-9. doi: 10.1016/j.tim.2025.05.004. Online ahead of print. Trends Microbiol. 2025. PMID: 40441928 Review.
Cited by
-
Small-Molecule Antibiotic Drug Development: Need and Challenges.ACS Infect Dis. 2023 Nov 10;9(11):2062-2071. doi: 10.1021/acsinfecdis.3c00189. Epub 2023 Oct 11. ACS Infect Dis. 2023. PMID: 37819866 Free PMC article. Review.
-
Phage therapy could be key to conquering persistent bacterial lung infections in children.NPJ Antimicrob Resist. 2024 Oct 10;2(1):31. doi: 10.1038/s44259-024-00045-4. NPJ Antimicrob Resist. 2024. PMID: 39843534 Free PMC article. Review.
-
Intracellular Pseudomonas aeruginosa persist and evade antibiotic treatment in a wound infection model.PLoS Pathog. 2025 Feb 13;21(2):e1012922. doi: 10.1371/journal.ppat.1012922. eCollection 2025 Feb. PLoS Pathog. 2025. PMID: 39946497 Free PMC article.
-
Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.PLoS Pathog. 2024 Oct 9;20(10):e1012595. doi: 10.1371/journal.ppat.1012595. eCollection 2024 Oct. PLoS Pathog. 2024. PMID: 39383167 Free PMC article. Review.
-
Phage vB_Kpn_HF0522: Isolation, Characterization, and Therapeutic Potential in Combatting K1 Klebsiella pneumoniae Infections.Infect Drug Resist. 2025 Feb 10;18:803-818. doi: 10.2147/IDR.S501921. eCollection 2025. Infect Drug Resist. 2025. PMID: 39958984 Free PMC article.
References
-
- Medina E., Pieper D.H. Tackling Threats and Future Problems of Multidrug-Resistant Bacteria. In: Stadler M., Dersch P., editors. How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives. Springer International Publishing; Cham, Switzerland: 2016. pp. 3–33.
-
- Nash A.A., Dalziel R.G., Fitzgerald J.R. Mims’ Pathogenesis of Infectious Disease. Elsevier; Amsterdam, The Netherlands: 2015. Failure to Eliminate Microbe; pp. 257–272.
-
- Perner A., Lassen A.T., Schierbeck J., Storgaard M., Reiter N., Benfield T. Disease burden and definition of sepsis in adults. Ugeskr. Laeger. 2018;180:V09170685. - PubMed
LinkOut - more resources
Full Text Sources